Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Afdhal, S Zeuzem, P Kwo, M Chojkier, N Gitlin, M Puoti, ... New England Journal of Medicine 370 (20), 1889-1898, 2014 | 2190 | 2014 |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial L Paz-Ares, EH Tan, K O’Byrne, L Zhang, V Hirsh, M Boyer, JCH Yang, ... Annals of Oncology 28 (2), 270-277, 2017 | 595 | 2017 |
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 543 | 2021 |
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 D Rodríguez-Abreu, SF Powell, MJ Hochmair, S Gadgeel, E Esteban, ... Annals of Oncology 32 (7), 881-895, 2021 | 431 | 2021 |
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer GR Oxnard, JCH Yang, H Yu, SW Kim, H Saka, L Horn, K Goto, Y Ohe, ... Annals of Oncology 31 (4), 507-516, 2020 | 382 | 2020 |
Overview of current systemic management of EGFR-mutant NSCLC WH Hsu, JCH Yang, TS Mok, HH Loong Annals of Oncology 29, i3-i9, 2018 | 361 | 2018 |
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus G Curigliano, S Banerjee, A Cervantes, MC Garassino, P Garrido, ... Annals of Oncology 31 (10), 1320-1335, 2020 | 342 | 2020 |
& Yuen, KY (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster JFW Chan, S Yuan, KH Kok, KKW To, H Chu, J Yang, F Xing, J Liu, ... The lancet 395 (10223), 514-523, 0 | 308 | |
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS … YL Wu, D Planchard, S Lu, H Sun, N Yamamoto, DW Kim, DSW Tan, ... Annals of Oncology 30 (2), 171-210, 2019 | 306 | 2019 |
Net global warming potential and greenhouse gas intensity of annual rice–wheat rotations with integrated soil–crop system management YC Ma, XW Kong, B Yang, XL Zhang, XY Yan, JC Yang, ZQ Xiong Agriculture, ecosystems & environment 164, 209-219, 2013 | 275 | 2013 |
Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study VA Papadimitrakopoulou, YL Wu, JY Han, MJ Ahn, SS Ramalingam, ... Annals of Oncology 29, viii741, 2018 | 270 | 2018 |
Effects of external phosphorus on the cell ultrastructure and the chlorophyll content of maize under cadmium and zinc stress HM Jiang, JC Yang, JF Zhang Environmental pollution 147 (3), 750-756, 2007 | 234 | 2007 |
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials G Goss, CM Tsai, FA Shepherd, MJ Ahn, L Bazhenova, L Crinò, ... Annals of Oncology 29 (3), 687-693, 2018 | 223 | 2018 |
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials JCH Yang, LV Sequist, C Zhou, M Schuler, SL Geater, T Mok, CP Hu, ... Annals of Oncology 27 (11), 2103-2110, 2016 | 203 | 2016 |
MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene J Yang, Z Zhang, C Chen, Y Liu, Q Si, TH Chuang, N Li, ... Oncogene 33 (23), 3014-3023, 2014 | 193 | 2014 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial M Schuler, JCH Yang, K Park, JH Kim, J Bennouna, YM Chen, C Chouaid, ... Annals of Oncology 27 (3), 417-423, 2016 | 166 | 2016 |
Effect of microvoids on initial and light‐degraded efficiencies of hydrogenated amorphous silicon alloy solar cells S Guha, J Yang, SJ Jones, Y Chen, DL Williamson Applied physics letters 61 (12), 1444-1446, 1992 | 146 | 1992 |
KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the … CJ Langer, SM Gadgeel, H Borghaei, VA Papadimitrakopoulou, A Patnaik, ... Lancet Oncol 17 (11), 1497-1508, 2016 | 140 | 2016 |
ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition HQ Ju, G Zhan, A Huang, Y Sun, S Wen, J Yang, WH Lu, RH Xu, J Li, Y Li, ... Leukemia 31 (10), 2143-2150, 2017 | 129 | 2017 |
Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: a multicenter, open-label, phase 1 trial JCH Yang, DR Camidge, CT Yang, J Zhou, R Guo, CH Chiu, GC Chang, ... Journal of Thoracic Oncology 15 (12), 1907-1918, 2020 | 127 | 2020 |